Literature DB >> 18434392

Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6.

Rajintha M Bandaranayake1, Moses Prabu-Jeyabalan, Junko Kakizawa, Wataru Sugiura, Celia A Schiffer.   

Abstract

The effect of amino acid variability between human immunodeficiency virus type 1 (HIV-1) clades on structure and the emergence of resistance mutations in HIV-1 protease has become an area of significant interest in recent years. We determined the first crystal structure of the HIV-1 CRF01_AE protease in complex with the p1-p6 substrate to a resolution of 2.8 A. Hydrogen bonding between the flap hinge and the protease core regions shows significant structural rearrangements in CRF01_AE protease compared to the clade B protease structure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434392      PMCID: PMC2447101          DOI: 10.1128/JVI.00018-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  HIV-1 nomenclature proposal.

Authors:  D L Robertson; J P Anderson; J A Bradac; J K Carr; B Foley; R K Funkhouser; F Gao; B H Hahn; M L Kalish; C Kuiken; G H Learn; T Leitner; F McCutchan; S Osmanov; M Peeters; D Pieniazek; M Salminen; P M Sharp; S Wolinsky; B Korber
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.

Authors:  Adrian Velazquez-Campoy; Sonia Vega; Ernesto Freire
Journal:  Biochemistry       Date:  2002-07-09       Impact factor: 3.162

4.  Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.

Authors:  Koyo Ariyoshi; Masakazu Matsuda; Hideka Miura; Sachiko Tateishi; Kaneo Yamada; Wataru Sugiura
Journal:  J Acquir Immune Defic Syndr       Date:  2003-07-01       Impact factor: 3.731

5.  Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development.

Authors:  Mario Sanches; Sandra Krauchenco; Nadia H Martins; Alla Gustchina; Alexander Wlodawer; Igor Polikarpov
Journal:  J Mol Biol       Date:  2007-03-24       Impact factor: 5.469

6.  Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.

Authors:  M J Gonzales; R N Machekano; R W Shafer
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

7.  Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.

Authors:  W R Scott; C A Schiffer
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

Review 9.  Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.

Authors:  Rami Kantor; David Katzenstein
Journal:  AIDS Rev       Date:  2003 Jan-Mar       Impact factor: 2.500

10.  Inhibition and catalytic mechanism of HIV-1 aspartic protease.

Authors:  A M Silva; R E Cachau; H L Sham; J W Erickson
Journal:  J Mol Biol       Date:  1996-01-19       Impact factor: 5.469

View more
  6 in total

1.  HIV-1 protease-substrate coevolution in nelfinavir resistance.

Authors:  Madhavi Kolli; Ayşegül Ozen; Nese Kurt-Yilmaz; Celia A Schiffer
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

2.  Effects of Hinge-region Natural Polymorphisms on Human Immunodeficiency Virus-Type 1 Protease Structure, Dynamics, and Drug Pressure Evolution.

Authors:  Zhanglong Liu; Xi Huang; Lingna Hu; Linh Pham; Katye M Poole; Yan Tang; Brian P Mahon; Wenxing Tang; Kunhua Li; Nathan E Goldfarb; Ben M Dunn; Robert McKenna; Gail E Fanucci
Journal:  J Biol Chem       Date:  2016-08-30       Impact factor: 5.157

3.  Subtype polymorphisms among HIV-1 protease variants confer altered flap conformations and flexibility.

Authors:  Jamie L Kear; Mandy E Blackburn; Angelo M Veloro; Ben M Dunn; Gail E Fanucci
Journal:  J Am Chem Soc       Date:  2009-10-21       Impact factor: 15.419

4.  New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors.

Authors:  Madhavi N L Nalam; Celia A Schiffer
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

5.  Role of Gag in HIV Resistance to Protease Inhibitors.

Authors:  François Clavel; Fabrizio Mammano
Journal:  Viruses       Date:  2010-07-05       Impact factor: 5.818

6.  Genetic Diversity and Low Therapeutic Impact of Variant-Specific Markers in HIV-1 Pol Proteins.

Authors:  Paloma Troyano-Hernáez; Roberto Reinosa; Africa Holguín
Journal:  Front Microbiol       Date:  2022-07-14       Impact factor: 6.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.